Bavarian Nordic's Q3 revenue exceeds DKK 1bn
The Danish biotech firm’s Q3 report released Wednesday morning shows the top line surpassing DKK 1bn, however skimming thin operating earnings.
BY CHRISTIAN BUNDGAARD, TRANSLATED BY DANIEL FRANK CHRISTENSEN
The monkeypox vaccine called Imavnex in Europe, and Jynneos in the US, gave Danish biotech group Bavarian Nordic a bit of tailwind in this year’s third quarter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
